Lir Life Sciences Completes Design of a Comparative Animal Study Investigating Cell-Penetrating Peptide-Mediated Delivery of GLP/GIP-Based Obesity Therapies

Executive Summary

• Lir Life Sciences announced the design of a controlled animal study to evaluate transdermal delivery of GLP‑1/GIP‑based obesity therapies using its novel cell‑penetrating peptide (CPP) platform.
• The study will compare skin‑permeation and glucose‑control efficacy of CPP‑enhanced transdermal formulations against standard subcutaneous injections for three clinically validated incretin drugs.
• Results are intended to guide candidate selection for IND‑enabling work and future clinical development of needle‑free obesity treatments.

Key Details

• Study Objective: Map performance envelope of Lir’s CPP‑enhanced transdermal platform across multiple GLP/GIP therapies; identify molecules best suited for needle‑free delivery.
• Design: Controlled animal study; subjects pre‑treated with transdermal formulations, followed by oral glucose challenge; blood glucose measured to assess delivery effectiveness.
• Comparisons: Transdermal CPP formulation vs. standard subcutaneous injection for each drug candidate.
• Therapies Evaluated: Three GLP‑1/GIP‑based obesity therapies (specific compounds not disclosed).
• Intended Outcome: Generate comparative data to prioritize strongest candidates for transdermal advancement and inform IND strategy.
• Strategic Rationale: Demonstrate that transdermal systems can improve comfort, accessibility, and adherence for chronic metabolic disease treatment.

Notable Quotes

“By evaluating three of the most clinically validated incretin therapies within the same delivery framework, we are generating the comparative data needed to prioritize the strongest candidates for transdermal advancement. Our aim with this study is to obtain clear insight into how these molecules behave with our CPP‑enabled system and to inform our IND strategy,” – Edward Mills, CEO, Lir Life Sciences.